C20ORF194 antibody - C-terminal region (ARP31848_T100)
- Known as:
- C20ORF194 (anti-) - C-terminal region (ARP31848_T100)
- Catalog number:
- arp31848_t100
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- C20ORF194 antibody - C-terminal region (ARP31848_T100)
Related genes to: C20ORF194 antibody - C-terminal region (ARP31848_T100)
- Gene:
- C20orf194 NIH gene
- Name:
- chromosome 20 open reading frame 194
- Previous symbol:
- -
- Synonyms:
- DKFZp434N061
- Chromosome:
- 20p13
- Locus Type:
- gene with protein product
- Date approved:
- 2003-01-30
- Date modifiied:
- 2016-09-30
Related products to: C20ORF194 antibody - C-terminal region (ARP31848_T100)
Related articles to: C20ORF194 antibody - C-terminal region (ARP31848_T100)
- Lung cancer remains the leading cause of cancer-related deaths worldwide, driven by its complexity and the heterogeneity of its subtypes, which influence pathogenesis, tumor microenvironment, and genetic alterations. We developed a novel weighted gene regulatory network reconstruction method based on maximum entropy and Markov chain entropy principles, which integrates gene expression and DNA methylation data to generate biologically informed networks. Applied to LUAD and LUSC datasets, we define a network methylation index to determine whether gene methylation acts as oncogenic or tumor-suppressive. By revealing a stable core set of pathogenic genes, we identify not only genes with significant expression changes, such as and , but also pathogenic genes with stable expression, such as and . Additionally, we uncover potential driver genes, such as and , associated with disease stage, gender, and smoking status. This method offers a more comprehensive understanding of NSCLC mechanisms, paving the way for improved therapeutic strategies. - Source: PubMed
Publication date: 2025/02/20
He QingcaiMi ZhilongYin ZiqiaoZheng ZhimingGuo Binghui - Noninvasive diagnostic markers that are capable of distinguishing patients with colorectal cancer (CRC) from healthy individuals or patients with other cancer types are lacking. We report the discovery and validation of a panel of methylation-based markers that specifically detect CRC. - Source: PubMed
Publication date: 2022/08/16
Li DapengZhang LeiFu JinmingHuang HaoLiu YanlongZhu LinSun HongruSun SiminZhang DingTian TianWang FanHu FulanPeng XiaolinLi GairuiZhao LiyuanZheng TingWang XuanCui BinbinZhao Yashuang - Globally, over 4% of the world population is affected by hepatitis C virus (HCV) infection. The current standard of care for hepatitis C infection is combination therapy with pegylated interferon and ribavirin for 48 weeks, which yield a sustained virological response in only a little over half of the patients with genotype 1 HCV. We investigated the clinical importance of pharmacogenetics in treatment efficacy and prediction of hematotoxicity. A total of 148 patients infected with HCV were enrolled. All patients were treated for a period of 48 weeks or less with pegylated interferon and ribavirin. Four genotypes were investigated: inosine triphosphatase (ITPA) rs1127354, C20orf194 rs6051702, interferon lambda (IFNL)3 rs8099917, IFNL3÷4 rs12979860 in the population from southwestern Romania. Genetic variants for rs129798660 and rs6051702 proved once more to represent an indisputable clinical tool for predicting sustained virological response (SVR) (69.23%, chi-square p=0.007846, p<0.05 and 63.29%, chi-square p=0.007846, p<0.05, respectively). ITPA genetic variants protect against ribavirin-induced hemolytic anemia and C20orf194 also proved to be protective against thrombocytopenia. These clinical findings strengthen the belief that pharmacogenetics should play a constant role in treatment decisions for patients infected with hepatitis C virus. - Source: PubMed
Kamal Adina MariaMitruŢ PaulKamal Kamal ConstantinTica Oana SorinaNiculescu MihaelaAlexandru Dragoş OvidiuTica Andrei Adrian - It has been found that ITPase deficiency is caused by ITPA gene polymorphisms. It was observed that ITPA polymorphisms have impact on hematological changes, including hemoglobin (Hb)-decline during treatment of chronic hepatitis C (CHC) patients with pegylated-interferon (PEG-IFN) plus ribavirin (RBV). - Source: PubMed
Publication date: 2016/02/20
Pouryasin MohammadKeshvari MaryamSharafi HeidarAlavian Seyed MoayedBehnava BitaAlavian Seyed EhsanPouryasin Ali - A high rate of sustained viral response (SVR) in Koreans with chronic hepatitis C (CHC) is related to a favorable IL28B genotype. We compared two dosing strategies for peginterferon alfa-2a in Koreans with CHC and defined the combined effect of polymorphisms and dosing on the virological response. - Source: PubMed
Publication date: 2013/10/23
Kwon Jung HyunBae Si HyunLee Youn JaeLee Jin-WooKim Young SeokHwang Jae SeokTak Won YoungJang Jeong WonLee Byung SeokLee June SungLee Chun KyonBaik Soon KooPark Neung HwaLee Tae HeeKim Dong JoonChoi Jae-SeokShin Jae-GookYim Hyeon Woo